32nd Ann Sym Email banner - FINAL

RedShiftBio at The Protein Society

The Protein Society's 32nd Annual Symposium hosts approximately 800 hundred chemists, biologists, physicists, mathematicians, students, and educators who share an interest in understanding the nature of proteins - a perfect place for us to showcase our new AQS3™pro.

Accurately characterizing structurally complex proteins is critical, yet results can be obstructed by deficiencies in today’s analytical techniques. RedShiftBio will be exhibiting the solution: a new spectroscopic platform for protein characterization, the AQS3™pro on booth 112 at The Protein Society. The AQS3pro will change how you measure protein and peptide structure.

“What sets MMS apart from circular dichroism spectroscopy,” said Professor Noel Lazo of Clark University, “is its ability to characterize proteins in solution at a wide range of concentrations and its greater sensitivity to β-sheet associated with protein aggregation.”

You can view our posters during the conference:

  • Comparability, Similarity, Linearity and High Order Structure Analysis of an IgG1 Sample by Microfluidic Modulation Spectroscopy (Libo Wang, Eugene Ma, Jeffrey Zonderman. RedShiftBio and Lucy Liu and Jason Rouse Pfizer)
  • Early Events in Amyloid Formation by Lysozyme Detected by Microfluidic Modulation Spectroscopy (Qiuchen Zheng, Valerie A. Ivancic, Libo Wang and Noel D. Lazo RedShiftBio)
  • Structural Characterization of the Insulin-Degrading Enzyme by Microfluidic Modulation Spectroscopy (Valerie A. Ivancic, Libo Wang and Noel D. Lazo RedShiftBio)

Can’t make it? Then register for our literature and we will send you the posters.


RedShiftBio® is an innovative provider of analytical instrumentation for the research, development and manufacturing of protein therapeutic drugs.

Read More



Contact Us

RedShift BioAnalytics Inc.

131 Middlesex Turnpike
Burlington, MA 01803

T: 781.345.7300
F: 781-345-7301
E: info@redshiftbio.com

RedShift™, RedShiftBio®,  See Change®, and AQS3™ are trademarks of RedShift BioAnalytics, Inc.